IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v36y2018i1d10.1007_s40273-017-0556-7.html
   My bibliography  Save this article

Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Author

Listed:
  • Hazel Squires

    (University of Sheffield)

  • Abdullah Pandor

    (University of Sheffield)

  • Praveen Thokala

    (University of Sheffield)

  • John W. Stevens

    (University of Sheffield)

  • Eva Kaltenthaler

    (University of Sheffield)

  • Mark Clowes

    (University of Sheffield)

  • Robert Coleman

    (University of Sheffield)

  • Lynda Wyld

    (University of Sheffield)

Abstract

As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer of pertuzumab (Perjeta®; Roche Products Limited) to submit evidence of its clinical and cost- effectiveness for the neoadjuvant treatment of women with high-risk, early-stage, HER2-positive breast cancer when used in combination with trastuzumab and chemotherapy. High-risk women included those with locally advanced (including inflammatory) breast cancer and women with high-risk early-stage breast cancer (classified as T2/3 or N1). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group. This article presents the critical review of the company’s submission by the Evidence Review Group and the outcome of the National Institute for Health and Care Excellence guidance. The clinical data were mainly taken from a phase II, randomised, open-label, active controlled study (NeoSphere), which reported a significant advantage in terms of pathological complete response rates of pertuzumab in combination with trastuzumab and chemotherapy, compared with trastuzumab alone with chemotherapy (45.8 vs. 29.0%, p = 0.0141). The company did not make any indirect comparisons. A meta-analysis of 12 neoadjuvant studies investigating the relationship between pathological complete response and event-free survival was used to extrapolate the outcomes reported in the NeoSphere study. A cardiac safety study (TRYPHAENA) demonstrated the safety of pertuzumab. The company undertook a model-based economic evaluation of neoadjuvant pertuzumab plus trastuzumab and docetaxel compared with neoadjuvant trastuzumab and docetaxel over a lifetime horizon from the National Health Service and Personal Social Services perspective. The probabilistic incremental cost-effectiveness ratio was estimated to be £20,104 per quality-adjusted life-year gained for pertuzumab alongside trastuzumab and docetaxel compared with trastuzumab and docetaxel, which was revised to £21,869 per quality-adjusted life-year gained following the clarification process. The Evidence Review Group corrected an error in the digitisation of the survivor functions and modified the clinically inappropriate assumption that recurrence is zero after 7 years. The Evidence Review Group’s probabilistic base case was £23,962 per quality-adjusted life-year gained. During the appraisal, to mitigate the uncertainties associated with the evidence, the company offered a patient access scheme, which led to the National Institute for Health and Care Excellence Appraisal Committee recommending pertuzumab in this patient group, subject to the company providing the agreed discount in the patient access scheme.

Suggested Citation

  • Hazel Squires & Abdullah Pandor & Praveen Thokala & John W. Stevens & Eva Kaltenthaler & Mark Clowes & Robert Coleman & Lynda Wyld, 2018. "Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 36(1), pages 29-38, January.
    • Handle: RePEc:spr:pharme:v:36:y:2018:i:1:d:10.1007_s40273-017-0556-7
    DOI: 10.1007/s40273-017-0556-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-017-0556-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-017-0556-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Unknown, 2016. "Department Publications 2014," Publications Lists 239845, University of Minnesota, Department of Applied Economics.
    2. Unknown, 2014. "Department Publications 2013," Publications Lists 206935, University of Minnesota, Department of Applied Economics.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Robert Koulish, 2016. "Using Risk to Assess the Legal Violence of Mandatory Detention," Laws, MDPI, vol. 5(3), pages 1-20, July.
    2. Morgan, Kimberly L. & Interis, Matthew G., 2017. "Who Buys More Directly from Producers in the Southeastern United States? A Research Note," Journal of Food Distribution Research, Food Distribution Research Society, vol. 48(2), July.
    3. Christopher Carroll & Paul Tappenden & Rachid Rafia & Jean Hamilton & Duncan Chambers & Mark Clowes & Paul Durrington & Nadeem Qureshi & Anthony S. Wierzbicki, 2017. "Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 35(5), pages 537-547, May.
    4. A. Duarte & C. Bojke & W. Cayton & A. Salawu & B. Case & L. Bojke & G. Richardson, 2018. "Impact of specialist rehabilitation services on hospital length of stay and associated costs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(7), pages 1027-1034, September.
    5. C Alexiou & J G Nellis, 2016. "A post-mortem of austerity: the Greek experience," Economic Issues Journal Articles, Economic Issues, vol. 21(2), pages 1-32, September.
    6. Paul Tappenden & Christopher Carroll & John W. Stevens & Andrew Rawdin & Sabine Grimm & Mark Clowes & Eva Kaltenthaler & John R. Ingram & Fiona Collier & Mohammad Ghazavi, 2017. "Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 35(8), pages 805-815, August.
    7. Kaplan, Jonathan D. & Norton, Max & Baumgartner, Kendra, 2018. "An ounce of prevention and a pound of cure: the substitutability or complementarity of grapevine trunk disease management practices," 2018 Annual Meeting, August 5-7, Washington, D.C. 274361, Agricultural and Applied Economics Association.
    8. Kim Loader, 2018. "Small- and medium-sized enterprises and public procurement: A review of the UK coalition government's policies and their impact," Environment and Planning C, , vol. 36(1), pages 47-66, February.
    9. Jacopo Arpetti & Antonio Iovanella, 2019. "Towards more effective consumer steering via network analysis," Papers 1903.11469, arXiv.org, revised Nov 2019.
    10. Jeremy Greenwood & Nezih Guner & Guillaume Vandenbroucke, 2017. "Family Economics Writ Large," Journal of Economic Literature, American Economic Association, vol. 55(4), pages 1346-1434, December.
    11. Mai, Nhat Chi, 2022. "Capital Raising and Management of Vietnamese Small and Medium Sized Enterprises after Integrating into Global Economy," OSF Preprints dv68m, Center for Open Science.
    12. Kate Golebiowska, 2016. "Are Peripheral Regions Benefiting from National Policies Aimed at Attracting Skilled Migrants? Case Study of the Northern Territory of Australia," Journal of International Migration and Integration, Springer, vol. 17(3), pages 947-971, August.
    13. Andrew Cleves & Paul Dimmock & Neil Hewitt & Grace Carolan-Rees, 2016. "The TURis System for Transurethral Resection of the Prostate: A NICE Medical Technology Guidance," Applied Health Economics and Health Policy, Springer, vol. 14(3), pages 267-279, June.
    14. Hongxing Liu & Wendong Zhang & Elena Irwin & Jeffrey Kast & Noel Aloysius & Jay Martin & Margaret Kalcic, 2020. "Best Management Practices and Nutrient Reduction: An Integrated Economic-Hydrologic Model of the Western Lake Erie Basin," Land Economics, University of Wisconsin Press, vol. 96(4), pages 510-530.
    15. Oliveira, Victor & Frazao, Elizabeth, 2015. "The WIC Program: Background, Trends, and Economic Issues, 2015 Edition," Economic Information Bulletin 197543, United States Department of Agriculture, Economic Research Service.
    16. Böhm, Sebastian & Grossmann, Volker & Strulik, Holger, 2021. "R&D-driven medical progress, health care costs, and the future of human longevity," The Journal of the Economics of Ageing, Elsevier, vol. 18(C).
    17. Evelina A. Zimovetz & Alain Joseph & Rajeev Ayyagari & Josephine A. Mauskopf, 2018. "A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 21-35, January.
    18. Mehri , N. & Messkoub, M. & Kunkel, S., 2019. "Trends, determinants and the implications of population aging in Iran," ISS Working Papers - General Series 646, International Institute of Social Studies of Erasmus University Rotterdam (ISS), The Hague.
    19. Mahdi Gharaibeh & Ali McBride & David S. Alberts & Brian Erstad & Marion Slack & Nimer Alsaid & J. Lyle Bootman & Ivo Abraham, 2018. "Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer," PharmacoEconomics, Springer, vol. 36(11), pages 1333-1343, November.
    20. Paul Cheshire & Stephen Gibbons & Jemma Mouland, 2017. "Social Tenants' Health: Evaluating the Effectiveness of Landlord Interventions," SERC Discussion Papers 0219, Centre for Economic Performance, LSE.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:36:y:2018:i:1:d:10.1007_s40273-017-0556-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.